290 related articles for article (PubMed ID: 12386648)
1. Simvastatin-induced lactic acidosis: a rare adverse reaction?
Goli AK; Goli SA; Byrd RP; Roy TM
Clin Pharmacol Ther; 2002 Oct; 72(4):461-4. PubMed ID: 12386648
[TBL] [Abstract][Full Text] [Related]
2. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M
Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451
[TBL] [Abstract][Full Text] [Related]
3. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity?
Tavintharan S; Ong CN; Jeyaseelan K; Sivakumar M; Lim SC; Sum CF
Toxicol Appl Pharmacol; 2007 Sep; 223(2):173-9. PubMed ID: 17610923
[TBL] [Abstract][Full Text] [Related]
4. [Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase].
Martinez-García FA; Martín-Fernández J; Moltó JM; Villaverde R; Morales A; Fernández-Barreiro A
Rev Neurol; 1997 Jun; 25(142):869-71. PubMed ID: 9244616
[TBL] [Abstract][Full Text] [Related]
5. HMG-CoA reductase inhibitors and coenzyme Q10.
Nawarskas JJ
Cardiol Rev; 2005; 13(2):76-9. PubMed ID: 15705257
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
[TBL] [Abstract][Full Text] [Related]
8. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis.
Johnson JL; Loomis IB
Pharmacotherapy; 2006 Mar; 26(3):414-22. PubMed ID: 16503723
[TBL] [Abstract][Full Text] [Related]
9. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
10. [Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and chlorzoxazone].
Bielecki JW; Schraner C; Briner V; Kuhn M
Schweiz Med Wochenschr; 1999 Apr; 129(13):514-8. PubMed ID: 10322565
[TBL] [Abstract][Full Text] [Related]
11. [Rhabdomyolysis and acute renal failure secondary to statins].
Borrego FJ; Liébana A; Borrego J; Pérez del Barrio P; Gil JM; García Cortés MJ; Sánchez Perales C; Serrano P; Pérez Bañasco V
Nefrologia; 2001; 21(3):309-13. PubMed ID: 11471312
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension.
Watanabe H; Kosuge K; Nishio S; Yamada H; Uchida S; Satoh H; Hayashi H; Ishizaki T; Ohashi K
Life Sci; 2004 Dec; 76(3):281-92. PubMed ID: 15531380
[TBL] [Abstract][Full Text] [Related]
13. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.
Nishio S; Watanabe H; Kosuge K; Uchida S; Hayashi H; Ohashi K
Hypertens Res; 2005 Mar; 28(3):223-7. PubMed ID: 16097365
[TBL] [Abstract][Full Text] [Related]
14. [Rhabdomyolysis as a side effect of simvastatin treatment].
Iskra B; Zivko M; Kes P
Acta Med Croatica; 2005; 59(4):325-8. PubMed ID: 16334740
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Kanathur N; Mathai MG; Byrd RP; Fields CL; Roy TM
Tenn Med; 2001 Sep; 94(9):339-41. PubMed ID: 11550401
[TBL] [Abstract][Full Text] [Related]
16. Development of thyroid follicular adenoma on simvastatin therapy.
McCord EL; Goenka S
Tenn Med; 2000 Jun; 93(6):210-2. PubMed ID: 10846948
[TBL] [Abstract][Full Text] [Related]
17. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
de Langen JJ; van Puijenbroek EP
Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
[TBL] [Abstract][Full Text] [Related]
18. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
Laaksonen R; Jokelainen K; Sahi T; Tikkanen MJ; Himberg JJ
Clin Pharmacol Ther; 1995 Jan; 57(1):62-6. PubMed ID: 7828383
[TBL] [Abstract][Full Text] [Related]
19. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
Andreou ER; Ledger S
Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320
[TBL] [Abstract][Full Text] [Related]
20. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
